Cellule CAR T: universo in espansione

1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018;378:439-48. doi: 10.1056/NEJMoa1709866. 2. Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol 2024;21:47-66. doi: 10.1038/s41571-023-00832-4. 3. Mougiakakos D, Krönke G, Völkl S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med 2021;385:567-9. doi: 10.1056/NEJMc210772. 4. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 2021;20:179-99. doi: 10.1038/s41573-020-00092-2. 5. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med 2024;390:687-700. doi: 10.1056/NEJMoa2308917. 6. Greco R, Alexander T, Del Papa N, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine 2024;69. doi: 10.1016/j.eclinm.2024.102476. 7. Oh S, Mao X, Manfredo-Vieira S, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol 2023;41:1229-38. doi: 10.1038/s41587-022-01637-z. 8. Beheshti SA, Shamsasenjan K, Ahmadi M, Abbasi B. CAR Treg: A new approach in the treatment of autoimmune diseases. Int Immunopharmacol 2022;102:108409. doi: 10.1016/j.intimp.2021. 108409. 9. Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature 2023;619: 707-15. doi: 10.1038/s41586-023-06243-w. 10. Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022;375(6576):91-96. doi: 10.1126/science.abm0594. 11. Seif M, Kakoschke TK, Ebel F, et al. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med 2022;14:eabh1209. doi: 10.1126/scitranslmed.abh1209. 12. Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 2020;583:127-32. doi: 10.1038/s41586-020-2403-9. 13. Magnani CF, Gaipa G, Lussana F, et al Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest 2020;130(11):6021-33. doi: 10.1172/ JCI138473. 14. Magnani CF, Gaipa G, Lussana F, et al. Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT. Blood 2021;138:472. doi: 10.1182/blood-2021-148703. 15. Gotti E, Tettamanti S, Zaninelli S, et al. Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. Cytotherapy 2022;24:334-43. doi: 10.1016/j.jcyt.2021.11.004. 16. Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The Past, Present, and Future of Non-Viral CAR T Cells. Front Immunol 2022;13. do: 10.3389/fimmu.2022.867013.